Ph.D., Founder & Chief Executive Officer, NuMedii
Gini Deshpande, PhD, is founder & CEO of NuMedii, a next generation biopharma company that pioneered the use of artificial intelligence and advanced data sciences to rapidly discover new precision therapeutics. As CEO, she structured critical partnerships with several large pharma companies and raised Series A from top tier VC firms. Previously, she helped Affymetrix and other companies with market development strategies for their ground-breaking technologies. She led innovation at Children’s Hospital Boston for the creation of new devices for the tiniest of patients and vaccines for the developing world. Gini helped commercialize early stage technologies in research tools, diagnostics & therapeutics and has closed licensing deals worth several million. Gini received her MS from the University of Pune (India), her PhD in Biological Sciences from Purdue University, and did post-doctoral work at the Massachusetts General Hospital.
Session Abstract – PMWC 2019 Silicon Valley
Session Synopsis: AI has the potential to expedite the pre-clinical drug design and discovery process. This session will provide a dive deep into different applications and AI platforms. Potential impact of such activities on the drug discovery and development processes, and on the strategic considerations in general in the pharmaceutical industry will be discussed.